Table 6.
Clinical studies and benefits.
| Disease (number of patients) | Treatment agent | Clinical benefit | Reference |
|---|---|---|---|
| Relapsed non-Hodgkin's lymphoma (60) | Ligustrazine | Higher overall response rate | [166] |
|
| |||
| Breast cancer (76) | Chinese magnolcavine fruit | Increase in response rate, delayed remission, and increase in the MRP negativity rate | [167] |
|
| |||
| Advanced gastrointestinal cancer (54) | Changweiqing formula | Higher response rate and Karnofsky score Longer survival time Lower level of MDR1 in blood cells |
[168] |
|
| |||
| Gastric cancer, stages II-III (30) | Didang formula | Higher response rate and better life quality Lower level of MDR1 in blood cells |
[169] |
|
| |||
| Liver cancer (71) | Xiaochaihu formula | Higher response rate and lower protein level of MDR1 in cancer tissue | [170] |
|
| |||
| Gastric cancer, stages II-III (60) | Shenqi Jianwei formula | Higher response rate, lower level of lower of CEA, and higher Karnofsky score | [171] |
|
| |||
| Breast cancer (60) | Pingxiao formula | Higher response rate and lower protein levels of MDR1 and GSTπ in cancer tissues | [172] |
|
| |||
| Breast cancer (53) | Fukangling capsule | Higher response rate and lower protein levels of MDR1 and GSTπ in cancer tissues | [173] |
|
| |||
| Non-small cell lung cancer (60) | Qiankun capsule | Lower level of blood TGF-α and lower number of PCNA positive cells as well as lower protein levels of LRP and MRP in cancer tissue | [174] |
|
| |||
| Breast cancer, stages II-III (33) | Fukangling capsule | Higher response rate and lower protein level of MDR1 in cancer tissue | [174] |